Pathomic immune biomarkers define recurrence risk in early-stage melanoma
Immune biomarkers should be prospectively validated in stage II-III melanoma for the purpose of avoiding overtreatment of low-risk patients and to stratify high-risk patients for clinical trials.
Authors
- Chaoyuan Kuang (ORCID: https://orcid.org/0000-0002-8984-3906)
- Swanand Rakhade
- Tammie Ferringer (ORCID: https://orcid.org/0000-0001-9701-5265)
- Thazin Nwe Aung (ORCID: https://orcid.org/0000-0003-4150-0426)
- Robyn D. Gartrell (ORCID: https://orcid.org/0000-0003-3287-4223)
- David L. Rimm (ORCID: https://orcid.org/0000-0001-5820-4397)
- Kent L. Nastiuk
- Matteo Abbruzzese (ORCID: https://orcid.org/0000-0002-5041-8056)
- Gerardo Espinoza
- Sharmin Sultana (ORCID: https://orcid.org/0000-0002-2398-3500)
- Lawrence W. Leung (ORCID: https://orcid.org/0000-0003-3333-3242)
- Basil A. Horst
- Jee‐Young Moon (ORCID: https://orcid.org/0000-0001-9218-8335)
- Yvonne M. Saenger (ORCID: https://orcid.org/0000-0001-7074-2681)
- David Entenberg (ORCID: https://orcid.org/0000-0003-0422-7264)
- Yadriel Bracero (ORCID: https://orcid.org/0009-0002-6483-4867)
- Suryansh Shukla
- Ajay Singh (ORCID: https://orcid.org/0000-0003-4969-7681)
- Chenxin Zhang (ORCID: https://orcid.org/0000-0002-4518-1322)
- Rui Chang (ORCID: https://orcid.org/0009-0000-5823-4799)
- Larisa J. Geskin (ORCID: https://orcid.org/0000-0001-7348-2571)
- Tianyun Jiang
- Divya Kenchappa
- Emily Nghiem (ORCID: https://orcid.org/0009-0001-5157-7198)
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Albert Einstein College of Medicine (US)
- University of Arizona (US)
- University of British Columbia (CA)
- Johns Hopkins University (US)
- Critical Path Institute (US)
- Johns Hopkins Bayview Medical Center (US)
- Yale University (US)
- Columbia College (CA)
- Geisinger Health System (US)
- Columbia University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf327
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Institutes of Health
- National Cancer Institute